FDA Warns GLP-1 Drugs Eye Risk

What happened

The outlets' own sentences, most widely reported first. Hover or tap one to see who reported it.

Analysis

How it changed

1. 9 Nov

   The FDA said “there is a potential increased risk of rare NAION” in people taking GLP-1 drugs.

   6 outlets · NBC News
2. 10 Nov

   FDA scientists began looking into the problem after the publication of a 2024 medical paper tying the condition to certain patients taking semaglutide, the active drug in Novo Nordisk's Ozempic and Wegovy.

   2 outlets · CBS News

Coverage 11 articles

• 11 Nov GLP-1 drugs to carry warning about rare vision-loss side effect, FDA saysThe FDA has announced that GLP-1 drugs will include warnings about a rare side effect that could result in vision loss. Dr. Rachel Pessah-Pollack is interviewed by CBS News to provide more details on this development.CBS News
• 10 Nov Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnessThe FDA has instructed manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. NAION occurs when blood vessels supplying the optic nerve are blocked, leading to vision loss that may be permanent. The FDA’s decision is based on its review of reports and…BBC
• 10 Nov FDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationsThe US FDA has issued a warning about GLP-1 weight loss medications, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua, due to the risk of nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. The FDA reviewed 126 clinical trials involving over 134,200 patients and found a higher incidence rate of NAION in GLP-1 users compared to…The Guardian
• 10 Nov FDA to require vision loss warning on GLP-1 drug labelsThe FDA announced on Monday that it will require drug labels for GLP-1 medications, including Ozempic and Wegovy, to include a warning about the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. Based on an analysis of over 125 clinical trials, the condition occurs in approximately six out of every 100,000 patients using GLP-1 drugs for at…Global News
• 10 Nov Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effectsThe Food and Drug Administration will require weight loss drugs like Ozempic and Wegovy to include warnings about a rare side effect that can lead to permanent vision loss due to non-arteritic anterior ischemic optic neuropathy. This condition, which has been reported with all GLP-1 drugs used for obesity and diabetes management, can result in significant vision impairment. The FDA initiated this review following a…Just the News
• 10 Nov Weight loss drugs linked to new rare side effect as new warning labels requiredThe U.S. Food and Drug Administration has required manufacturers of weight-loss drugs like Ozempic and Wegovy to include warnings about a rare eye condition called NAION that can lead to permanent vision loss. The FDA’s decision, made after reviewing reports from over 134,000 patients, found an increased risk of six cases per 100,000 people annually for those taking GLP-1 drugs compared to about four cases among…The Independent
• 10 Nov GLP-1s must now include warning for potential increased risk of vision loss, FDA announcesIt appears there might be a mismatch between the title and the article text provided. The title discusses the FDA announcing that GLP-1 drugs must now carry warnings about an increased risk of vision loss. However, the text given is unrelated and mentions Hegseth being accused of high crimes and misdemeanors. Without the relevant content discussing GLP-1 drugs or FDA regulations, I cannot summarize the specific…CBS News
• 10 Nov FDA warns of rare vision-loss side effect from GLP-1 drugsThe U.S. Food and Drug Administration (FDA) has issued a new warning about a rare but serious side effect associated with GLP-1 drugs, including popular brands like Ozempic and Wegovy. This warning alerts users to the risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. The FDA’s decision follows an analysis of clinical trials involving more than 125 studies…CBS News
• 9 Nov GLP-1 drugs must have new warning label over incurable blindness condition, says FDAThe FDA has mandated that manufacturers update warning labels on GLP-1 drugs like Ozempic and Wegovy to include a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can lead to permanent vision loss or blindness. This decision follows a study showing diabetes patients taking semaglutide are four times more likely to develop NAION compared to those not using the drug…New York Post
• 9 Nov FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindnessThe Food and Drug Administration has mandated that manufacturers of GLP-1 drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION) which can cause sudden blindness. This decision follows research indicating an increased risk of NAION in patients using GLP-1 medications…NBC News

Keep exploring

Similar coverageGLP-1 Drug Lawsuits Vision Loss Similar coverageOzempic Linked To Blindness Claims Similar coverageTGA Clears GLP-1 Weight Loss Pills Similar coverageFDA Inspectors Find Issues In Chinese Plants RecentSenior US Soldier Arrested In UK On Spying Charges RecentNvidia Investigates CEO Affair RecentThomas Markle Cut Off Ankle Monitor RecentQantas Job Cuts and Outsourcing RecentKirk Cousins Traded Back to Vikings RecentUS Charges Iranian Operatives Terror Plots